RecruitingPhase 2NCT06830629
A Phase 2 Study of MZE829 in Adults With APOL1 Kidney Disease
An Open-Label Phase 2 Study to Evaluate the Safety, Tolerability, and Effect on Albuminuria of MZE829 in Adults With Proteinuric Chronic Kidney Disease and the APOL1 High Risk Genotype
Sponsor
Maze Therapeutics
Enrollment
56 participants
Start Date
Feb 5, 2025
Study Type
INTERVENTIONAL
Conditions
Summary
This is purpose of this study is to evaluate the safety, tolerability, and effect on Albuminuria of MZE829 in Adults with APOL1 Kidney Disease
Eligibility
Min Age: 18 YearsMax Age: 68 Years
Inclusion Criteria2
- APOL1 high risk genotype of G1/G1, G2/G2, or G1/G2
- Chronic kidney disease with persistent albuminuria
Exclusion Criteria5
- Organ or bone marrow transplantation
- History of cancer within past 2 years, excepted for treated non-melanoma skin cancer, stage 0 cervical cancer, or stage 1 prostate cancer
- Conditions that may alter drug absorption, e.g., history of bariatric surgery
- Type I diabetes
- Pregnant or currently nursing
Interventions
DRUGMZE829
Capsules for oral administration
Locations(74)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06830629